Emerging strategies for the treatment of Alzheimer's disease at the millennium

Emerging Drugs

Volumn 4, Issue , 1999, Pages 35-86

  Emmerling, M R ^a   Spiegel, K ^a   Hall, E D ^a   LeVine, H ^a   Walker, L C ^a   Schwarz, R D ^a   Gracon, S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 AZABICYCLO[2.2.1]HEPTAN 3 ONE O [3 (3' METHOXYPHENYL) 2 PROPYNYL]OXIME MALEATE; 2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; 5 CYCLOHEXYL 1 (4 IMIDAZOL 4 YLPIPERIDYL)PENTAN 1 ONE; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; APAXAFYLLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; MUSCARINIC AGENT; N ALPHA (2 METHYL 4 OXO CYCLOPENTANECARBONYL)HISTIDYLPROLINAMIDE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINIC AGENT; NOOTROPIC AGENT; PHYSOSTIGMINE; RIVASTIGMINE; SABELUZOLE; SCAVENGER; SIDOPIRIDINE; SYNAPTON; TACRINE; TALSACLIDINE; TIRALIZAD MESYLATE; U 98222; U 98950; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; HUMAN; REVIEW; SIDE EFFECT;

EID: 0032908179     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.4.1.35     Document Type: Review

References (303)